HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SYNPO2
synaptopodin 2
Chromosome 4 · 4q26
NCBI Gene: 171024Ensembl: ENSG00000172403.11HGNC: HGNC:17732UniProt: B4DLE4
48PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Tumor Suppressor
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
stress fiberalpha-actinin bindingactin cytoskeletonZ discneurodegenerative diseasediaphragmatic herniaoral mucosa leukoplakiadislocation
✦AI Summary

SYNPO2 (synaptopodin 2) is an actin-binding protein that primarily regulates cytoskeletal organization and cell migration. It promotes formation of nascent focal adhesions, actin bundles at the cell leading edge, and lamellipodia through Rho-ROCK cascade signaling 12. In muscle tissues, SYNPO2 localizes to Z-discs in striated muscle and dense bodies in smooth muscle, where it interacts with α-actinin, filamin C, and synemin to maintain contractile structure under mechanical stress 3. SYNPO2 functions as a critical checkpoint in vascular smooth muscle cells, preventing pathological phenotypic switching during arterial remodeling associated with atherosclerosis and aortic aneurysms 4. In cancer pathology, SYNPO2 shows context-dependent roles. Reduced expression correlates with poor hepatocellular carcinoma prognosis, with nuclear-cytoplasmic translocation via calcineurin promoting metastasis 5. Conversely, in colorectal cancer under hypoxia, SYNPO2 suppresses progression by inhibiting the YAP-KLF5 axis 6. In bladder carcinoma, elevated SYNPO2 promotes tumor development through mast cell infiltration and immunotherapy resistance 7. High SYNPO2 expression associates with poor survival in nasopharyngeal carcinoma 8. Additionally, SYNPO2 participates in selective autophagy pathways through BAG3 interactions 9 and may contribute to myofibrillar pathology 10.

Sources cited
1
SYNPO2 promotes formation of nascent focal adhesions and actin bundles via Rho-ROCK cascade
PMID: 22915763
2
SYNPO2 promotes actin cytoskeletal organization at cell leading edge and lamellipodia
PMID: 25883213
3
SYNPO2 localizes to Z-discs in striated muscle and dense bodies in smooth muscle, interacts with α-actinin, filamin C, and synemin
PMID: 38201288
4
SYNPO2 acts as checkpoint preventing VSMC pathological phenotypic switching in arterial diseases
PMID: 40516911
5
SYNPO2 reduced expression correlates with poor HCC prognosis; calcineurin-induced nuclear-cytoplasmic translocation promotes metastasis
PMID: 32278815
6
SYNPO2 suppresses colorectal cancer progression under hypoxia by regulating YAP-KLF5 axis
PMID: 34333382
7
High SYNPO2 expression promotes bladder carcinoma development through mast cell infiltration and immunotherapy resistance
PMID: 38038167
8
High SYNPO2 expression is unfavorable prognostic factor in nasopharyngeal carcinoma
PMID: 37505159
9
SYNPO2 interacts with BAG3 and participates in autophagy and mitophagy
PMID: 34889472
10
SYNPO2 is identified in phosphoproteomics assay related to filamin C turnover in myofibrillar myopathy context
PMID: 37427997
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.37Weak
diaphragmatic herniaOpen Targets
0.30Weak
oral mucosa leukoplakiaOpen Targets
0.28Weak
dislocationOpen Targets
0.24Weak
nasopharyngeal carcinomaOpen Targets
0.07Suggestive
Blackfan-Diamond anemiaOpen Targets
0.07Suggestive
breast cancerOpen Targets
0.06Suggestive
bladder transitional cell carcinomaOpen Targets
0.06Suggestive
primary familial polycythemia due to EPO receptor mutationOpen Targets
0.06Suggestive
Alpha-thalassemia - myelodysplastic syndromeOpen Targets
0.05Suggestive
alpha-thalassemia-myelodysplastic syndromeOpen Targets
0.05Suggestive
hemoglobin D diseaseOpen Targets
0.05Suggestive
hereditary persistence of fetal hemoglobin-sickle cell disease syndromeOpen Targets
0.05Suggestive
Hereditary persistence of fetal hemoglobin - beta-thalassemiaOpen Targets
0.05Suggestive
neoplasmOpen Targets
0.05Suggestive
X-linked sideroblastic anemia 1Open Targets
0.05Suggestive
alpha thalassemia-intellectual disability syndrome type 1Open Targets
0.05Suggestive
Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16Open Targets
0.05Suggestive
autosomal dominant sideroblastic anemiaOpen Targets
0.05Suggestive
Constitutional sideroblastic anemiaOpen Targets
0.05Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
FLNAProtein interaction79%ACTN2Protein interaction74%BAG3Protein interaction73%HSPB8Protein interaction73%FLNCProtein interaction71%PFN3Shared pathway33%
Tissue Expression6 tissues
Heart
100%
Ovary
44%
Lung
24%
Brain
14%
Liver
6%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
SYNPO2FLNAACTN2BAG3HSPB8FLNCPFN3
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9UMS6
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.76LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.61 [0.49–0.76]
RankingsWhere SYNPO2 stands among ~20K protein-coding genes
  • #9,142of 20,598
    Most Researched48
  • #6,153of 17,882
    Most Constrained (LOEUF)0.76
Genes detectedSYNPO2
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Synaptopodin-2 promotes hepatocellular carcinoma metastasis via calcineurin-induced nuclear-cytoplasmic translocation.
PMID: 32278815
Cancer Lett · 2020
1.00
2
Cytoskeletal-related genes function as checkpoints for the maintenance of VSMC contractile phenotype and prevent pathological remodeling in arterial diseases.
PMID: 40516911
J Adv Res · 2026
0.90
3
Synaptopodin-2 Isoforms Have Specific Binding Partners and Display Distinct, Muscle Cell Type-Specific Expression Patterns.
PMID: 38201288
Cells · 2023
0.80
4
Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.
PMID: 25918983
J Invest Dermatol · 2015
0.70
5
SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy.
PMID: 38038167
Oncol Rep · 2024
0.60